Boston Scientific (BSX) closed at $44.20 on November 12, 2026, down 2.1% from the previous close, on volume of 10,278,002 shares (30-day average 18,036,675).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Call Spread | 18-Dec-2667.5 : 85 C | 212,004 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
PRNewswire (Thu, 12-Nov 10:35 AM ET)
Business Wire (Thu, 5-Nov 4:00 PM ET)
Business Wire (Mon, 2-Nov 5:54 PM ET)
SIMPLAAFY study of the WATCHMAN FLX Pro Left Atrial Appendage Closure Device meets primary endpoints
PRNewswire (Mon, 2-Nov 2:03 PM ET)
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
PRNewswire (Thu, 29-Oct 4:05 PM ET)
Boston Scientific announces results for third quarter 2026
PRNewswire (Wed, 28-Oct 6:31 AM ET)
Boston Scientific to participate in Stifel's 2026 Healthcare Conference
PRNewswire (Mon, 26-Oct 8:00 AM ET)
Business Wire (Thu, 22-Oct 8:30 AM ET)
Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
PRNewswire (Wed, 7-Oct 6:00 AM ET)
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Globe Newswire (Thu, 1-Oct 4:45 PM ET)
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Boston Scientific trades on the NYSE stock market under the symbol BSX.
As of November 12, 2026, BSX stock price declined to $44.20 with 10,278,002 million shares trading.
BSX has a beta of 0.35, meaning it tends to be less sensitive to market movements. BSX has a correlation of 0.01 to the broad based SPY ETF.
BSX has a market cap of $65.69 billion. This is considered a Large Cap stock.
Last quarter Boston Scientific reported $5 billion in Revenue and $.73 earnings per share. This beat revenue expectation by $61 million and met earnings estimates .
In the last 3 years, BSX traded as high as $109.50 and as low as $39.57.
The top ETF exchange traded funds that BSX belongs to (by Net Assets): VTI, VOO, IVV, SPY, VO.
BSX has underperformed the market in the last year with a return of -56.9%, while the SPY ETF gained +12.0%. In the last 3 month period, BSX fell short of the market, returning -13.7%, while SPY returned -1.5%. However, in the most recent 2 weeks BSX has outperformed the stock market by returning +4.2%, while SPY returned -2.0%.
BSX support price is $43.95 and resistance is $46.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BSX shares will trade within this expected range on the day.
